Barbell Medicine

What Happens When You Stop a GLP-1: The Data From Three Trials

The video dissects recent evidence on how durable the weight‑loss and cardiovascular benefits of GLP‑1 receptor agonists are once the drugs are stopped. It centers on a British Medical Journal analysis and three pivotal trials—SURMOUNT‑4, STEP‑1 extension, and a semaglutide series—while contrasting them with intensive lifestyle‑only programs. Across the studies, roughly two‑thirds of the weight shed on a GLP‑1 is regained within 12 months after discontinuation. In SURMOUNT‑4, participants lost ~20 % of body weight on tirzepatide; those who stayed on the drug lost an additional 5.5 % over the next year, whereas the placebo arm regained about 14 % of the loss. The STEP‑1 extension showed a net 5.5 % sustained loss after 120 weeks, with half of participants still ≤5 % above baseline. A systematic review of 48 trials reported a faster early regain, plateauing around week 60, with similar percentage trajectories across agents. The presenter cites classic lifestyle trials—DPP, Look AHEAD, and the Pounds‑Lost study—to illustrate that even intensive counseling yields modest losses (5‑9 % at one year) and substantial regain (over 50 % by 4‑10 years). By contrast, GLP‑1 trials achieved 70‑80 % of participants reaching ≥10 % loss, a magnitude far beyond lifestyle alone, explaining why absolute regain appears larger. The findings suggest that stopping GLP‑1 therapy erodes most of its advantage, underscoring the importance of long‑term pharmacologic support or realistic patient counseling. For payers and clinicians, the data highlight the trade‑off between short‑term efficacy and the cost of indefinite treatment in obesity management.